Fennec Pharmaceuticals Inc. (FRA:RV41)

Market Cap	176.85M +14.8%
Revenue (ttm)	38.02M -6.1%
Net Income	-8.30M
EPS	-0.29
Shares Out	n/a
PE Ratio	n/a
Forward PE	60.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	5.40
Previous Close	5.30
Day's Range	5.10 - 5.40
52-Week Range	4.30 - 8.25
Beta	n/a
RSI	26.62
Earnings Date	Mar 24, 2026

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the ri...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 32
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RV41

Financial Performance

In 2025, Fennec Pharmaceuticals's revenue was $44.64 million, a decrease of -6.09% compared to the previous year's $47.54 million. Losses were -$9.74 million, 2134.2% more than in 2024.

Financial numbers in USD